Genotoxicity assessed by the Comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 330-343

  Escobar, Patricia A ^a   Olivero, Ofelia A ^b   Wade, Nancy A ^c   Abrams, Elaine J ^d   Nesel, Carol J ^e   Ness, Roberta B ^f   Day, Richard D ^f   Day, Billy W ^a   Meng, Quanxin ^g,h   O'Neill, J Patrick ⁱ   Walker, Dale M ^g,h   Poirier, Miriam C ^b   Walker, Vernon E ^g,h   Bigbee, William L ^a,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d Harlem Hospital Center ^*  (United States)

^e WESTAT   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g WADSWORTH CENTER   (United States)

^h LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF VERMONT   (United States)

Author keywords

AZT DNA incorporation; Comet assay; Glycophorin A mutations; Lamivudine; Transplacental mutagenicity; Zidovudine

Indexed keywords

CELL DNA; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CARCINOGEN DNA INTERACTION; CHEMICAL MUTAGENESIS; CHROMOSOME DUPLICATION; CHROMOSOME LOSS; COHORT ANALYSIS; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; ERYTHROCYTE; GENE CONVERSION; GENE FREQUENCY; GENE MUTATION; GENOTOXICITY; GPA GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INFANT; LYMPHOBLASTOID CELL; MITOTIC RECOMBINATION; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; NEWBORN; PERINATAL DRUG EXPOSURE; RADIOIMMUNOASSAY; REPORTER GENE; SOMATIC MUTATION; UMBILICAL CORD BLOOD;

ANTI-HIV AGENTS; CELL LINE; COMET ASSAY; DRUG COMBINATIONS; ERYTHROCYTES; FEMALE; GLYCOPHORIN; HUMANS; INFANT; INFANT, NEWBORN; LAMIVUDINE; LEUKOCYTES; MATERNAL-FETAL EXCHANGE; MUTAGENICITY TESTS; MUTATION; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34047202134     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20285     Document Type: Article

References (58)

1. Albertini RJ, Nicklas JA, O'Neill JP, Robbins SH. 1990. In vivo somatic mutations in humans: Measurement and analysis. Annu Rev Genet 24:305-326.
2. Ayers KM, Clive D, Tucker WE Jr., Hajian G, de Miranda P. 1996. Nonclinical toxicology studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 32:148-158.
3. Ayers KM, Torrey CE, Reynolds DJ. 1997. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 38:195-198.
4. Balachandran R, ter Haar E, Yalowich JC, Welsh MJ, Grant SG, Day BW. 1999. Induction of human breast cancer cell apoptosis from G2/M preceded by stimulation into the cell cycle by Z-1,1-dichloro-2, 3-diphenylcyclopropane. Biochem Pharmacol 57:97-110.
5. Capparelli E, Rakhmanina, Mirochnick M. 2005. Pharmacotherapy of perinatal HIV-1. Seminars in Fetal and Neonatal Medicine 10:151-175.
6. Connor EM, Sperling RS, Belber R, Kiselev P, Scott G, O'Sullivan JM, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Station P, Balsley J, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:1173-1180.
7. Daniel CP, Fisher A, Parker L, Burn J, Tawn EJ. 2000. Individual variation in somatic mutations of the glycophorin-A gene in neonates in relation to pre-natal factors. Mutat Res 467:153-159.
8. Dertinger SD, Torous DK, Tometsko KR. 1996. Induction of micronuclei by low doses of azidothymidine (AZT). Mutat Res 368:301-307.
9. Diwan BA, Riggs CW, Logsdon D, Haines DC, Olivero OA, Rice JM, Yuspa SH, Poirier MC, Anderson LM. 1999. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol Appl Pharmacol 161:82-99.
10. Fairbairn DW, Olive PL, O'Neill KL. 1995. The comet assay: A comprehensive review. Mutat Res 339:37-59.
11. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, Barry DW. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphsophate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83:8333-8337.
12. Grant SG. 2005. The GPA in vivo somatic mutation assay. Methods Mol Biol 291:179-195.
13. Grant SG, Bigbee WL. 1993. In vivo somatic mutation and segregation at the human glycophorin A (GPA) locus: Phenotypic variation encompassing both gene-specific and chromosomal mechanisms. Mutat Res 288:163-172.
14. Hashiguchi K, Bohr VA, De Sousa-Pinto NC. 2004. Oxidative stress and mitochondrial DNA repair: Implications for NRTIs induced DNA damage. Michondrion 4:215-222.
15. Hong LH, Dunnick J, Herbert R, Devereux TR, Kim Y, Sills RC. 2007. Genetic alterations in K.-ras and p53 cancer genes in lung neoplasms of Swiss (CD-1) male mice following AZT transplacental exposure. Environ Mol Mutagen 48:299-306.
16. IARC. 2000. General remarks; and the monograph on zidovudine. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. IARC Scientific Publication No. 76, Lyon, pp 35-42 and 73-127.
17. Jensen RH, Bigbee WL. 1996. Direct immunofluorescence labeling provides an improved method for the glycophorin: A somatic cell mutation assay. Cytometry 23:337-343.
18. Langlois RG, Bigbee WL, Jensen RH. 1986. Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus. Hum Genet 74:353-362.
19. Lehninger AL, Nelson DL, Cox MM. 1993. Principles of Biochemistry. New York: Worth Publishers, p 344.
20. Mclntyre J. 2006. Strategies to prevent mother-to-child transmission of HIV-1. Curr Opin Infect Dis 19:33-38.
21. McKelvey-Martin VJ, Green MH, Schmezer P, Pool-Zobel BL, De Meo MP, Collins A. 1993. The single cell gel electrophoresis assay (comet assay): A European review. Mutat Res 288:47-63.
22. Mediavilla MD, Sanchez-Barcelo EJ. 2000. Doses and time-dependent effects of 3′-azido-3′-deoxythymidine on T47D human breast cancer cells in vitro. Pharmacol Toxicol 87:138-143.
23. Meng Q, Su T, Olivero OA, Poirier MC, Shi X, Ding X, Walker VE. 200Oa. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Toxicol Sci 54:322-9.
24. Meng Q, Grosovsky AJ, Shi X, Walker VE. 200Ob. Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Mutagen 15:405-410.
25. Meng Q, Walker DM, Olivero OA, Shi X, Antiochos BB, Poirier MC, Walker VE. 200Oc. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci USA 97:12667-71.
26. Meng Q, Su T, O'Neill P, Walker VE. 2002. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′-azido-3′-deoxythy-midine and 2′,3′-dideoxyinosine. Environ Mol Mutagen 39:282-295.
27. Meng Q, Olivero OA, Fasco MJ, Bellisario R, Kaminsky L, Pass KA, Abrams E, Wade N, Poirier MC, Walker VE, protocol team. 2007. Plasma and cellular markers of AZT metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs. Environ Mol Mutagen 48:307-321.
28. Mittelstaedt RA, Von Tungeln LS, Shaddock JG, Dobrovolsky VN, Beland FA, Heflich RH. 2004. Analysis of mutations in the Tk gene of Tk(+/-) mice treated as neonates with 3′-azido-3′-deoxy-thymidine (AZT). Mutat Res 547:63-69.
29. Mokkapati SK, Wiederfhold L, Hazra TK, Miter S. 2004. Stimulation of DNA glycosylase activity of OOG1 by NEILl: Functional collaboration between two human DNA glycosylases. Biochem 43:11596-11604.
30. Olive PL, Banath JP, Durand RE. 199Oa. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 122:86-94.
31. Olive PL, Banath JP, Durand RE. 199Ob. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst 82:779-783.
32. Olivero OA. 2007. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 48:215-223.
33. Olivero OA, Beland FA, Fullerton NF, Poirier MC. 1994a. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′, 3′-dideoxythymidine. Cancer Res 54:6235-6242.
34. Olivero OA, Beland FA, Poirier MC. 1994b. Immunofluorescent localization and quantitation of 3′-azido-2′, 3′-dideoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster and mouse cell lines. Int J Oncol 4:49-54.
35. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplacental effects of 3′-azido-2′,3′-dideoxy-thymidine (AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
36. O'Neill JP, Gundel RM, Trombley LM, Walker VE. 2001. HPRT mutant frequency and mutation spectra in newborns with perinatal exposure to antiviral drugs. Environ Mol Mutagen 37 (Suppl. 32):58.
37. Poirier MC, Olivero OA, Walker DM, Walker VE. 2004. Perinatal genotoxicity and carcinogenicity of the antiretroviral nucleoside analog drugs. Toxicol Appl Pharmacol 199:151-161.
38. Sailaja G, Nayak R, Antony A. 1996. Azidothymidine induces apoptosis in mouse myeloma cell line Sp2/0. Biochem Pharmacol 52:857-862.
39. Senda S, Blanche S, Costagliola D, Cibert C, Nigon F, Firtion G, Floch C, Parat S, Viegas-Péquignot E. Altered heterochromatin organization after perinatal exposure to zidovudine (AZT). Antiviral Therapy (in press).
40. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
41. Slamenova D, Horvathova E, Bartkova M. 2006. Nature of DNA lesions induced in human hepatoma cells, human colonic cells and human embryonic lung flbroblasts by the antiretroviral drug 3′-azido-3′-deoxythymidine. Muta Res 593:97-107.
42. Stiehm ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, Nugent R, Moye J Jr., Glenn FM, Mathieson BJ, Reichelderfer P, Nemo GJ, Korelitz J, Meyer WA III, Sapan CV, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H. 1999. Efficacy of zidovudine and human immunodeficiency virus (HIV-1) hyperimmune immunoglobulin for reducing perinatal HlV-1 transmission from HIV-1-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 179:567-575.
43. Sukhanova MV, Khodyreva SN, Ldbedeva NA, Prasad R, Wilson SH, Lavrik OI. 2005. Human base excision repair enzymes apurinic/apyrimidinic endonucleasel (APE1), DNA polymerase beta and poly(ADP-ribose) polymerase 1: Interplay between strand-displacement DNA synthesis and proofreading exonuclease activity. Nucl Acid Res 33:1222-1229.
44. Sussman HE, Olivero OA, Meng Q, Pietras SM, Poirier MC, O'Neill JP, Finette BA, Bauer MJ, Walker VE. 1999. Genotoxicity of 3′-azido-3′- deoxythymidine in the human lymphoblastoid cell line, TK-6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. Mutat Res 429:249-259.
45. Tice RR, Strauss GH. 1995. The single cell gel electrophoresis/comet assay: A potential tool for detecting radiation-induced DNA damage in humans. Stem Cells 13 (Suppl. 1):207-214.
46. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
47. Tomici MT, Thust R, Sobol RW, Kaina B. 2001. DNA polymerase beta mediates protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA breakage. Cancer Res 61:7399-7403.
48. Torres SM, Walker DM, Carter MM, Cook DL Jr., McCash CL, Cordova EM, Olivero OA, Poirier MC, Walker VE. 2007. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen 48:224-238.
49. Viora M, Di Genova G, Rivabene R, Malorni W, Fattorossi A. 1997. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs. Int J Immunopharmacol 19:311-321.
50. Von Tungeln LS, Hamilton LP, Dobrovolsky VN, Bishop ME, Shaddock JG, Heflich RH, Beland FA. 2002. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F(1)/Tk+/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis 23(9):1427-1432.
51. Von Tungeln LS, Dobrovolsky VN, Bishop ME, Shaddock JG, Heflich RH, Beland FA. 2004. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine. Mutagen 19:307-311.
52. Von Tungeln LS, Williams LD, Doerge DR, Shaddock JG, McGarrity LJ, Morris SM, Mittelstaedt RA, Heflich RH, Beland FA. 2007. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ Mol Mutagen 48:258-269.
53. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT. Wang L, Baum JB, Tesoriero JM, Savicki R. 1998. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 339:1409-1414.
54. Walker DM, Malarkey DE, Seilkop SK, Ruecker FA, Funk KA, Wolfe MJ, Treanor CP, Foley JF, Dunnick JK, Hardisty JF, Walker VE. 2007. Transplacental carcinogenicity of 3′-azido-3′-deoxythymidine in B6C3F1 mice and F344 rats. Environ Mol Mutagen 48:283-298.
55. Walker VE, Wade N, Abrams E, Ness RB. 2001. Observational cohort study of the genotoxic risks arising from perinatal NRTI therapies. Environ Mol Mutagen 37 (Suppl. 32):77.
56. Witt KL, Tice RR, Wolfe GW, Bishop JB. 2004. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment. Environ Mol Mutagen 44:321-328.
57. Witt KL, Cunningham CK, Patterson KB, Kissing GE, Dertinger SD, Livingston E, Bishop JB. 2007. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen 48:322-329.
58. Zhang Z, Diwan BA, Anderson LM, Logsdon D, Olivero OA, Haines DC, Rice JM, Yuspa SH, Poirier MC. 1998. Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3′-azido-2′, 3′-dideoxythymidine. Mol Carcinog 23:45-51.